Mirum Pharmaceuticals
(NASDAQ) MIRM
Mirum Pharmaceuticals Financials at a Glance
Market Cap
$7.01B
Revenue (TTM)
$569.61M
Net Income (TTM)
-$798.84M
EPS (TTM)
-$13.60
P/E Ratio
-8.45
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Price
$118.80
Volume
2,807
Open
$113.72
Price
$118.80
Volume
2,807
Open
$113.72
Previous Close
$114.97
Daily Range
$113.22 - $119.49
52-Week Range
$47.89 - $119.49
Estimated Earnings Date
Jul 30, 2026
Dividend
$0.00
Beta (Volatility)
0.75 (Low)
Price
$118.80
Volume
2,807
Open
$113.72
Previous Close
$114.97
Daily Range
$113.22 - $119.49
52-Week Range
$47.89 - $119.49
Estimated Earnings Date
Jul 30, 2026
MIRM News
MIRM: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Mirum Pharmaceuticals
Industry
Biotechnology
Sector
Health CareEmployees
372
CEO
Christopher Peetz, MBA
Website
www.mirumpharma.comHeadquarters
Foster City, CA 94404, US
MIRM Financials
Key Financial Metrics (TTM)
Gross Margin
81.36%
Operating Margin
-12.31%
Net Income Margin
-140.24%
Return on Equity
-289.33%
Return on Capital
-3.49%
Return on Assets
-89.67%
Earnings Yield
-11.83%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$7.01B
Shares Outstanding
60.98M
Volume
2.81K
Avg. Volume
954.75K
Financials (TTM)
Gross Profit
$463.43M
Operating Income
-$70.12M
EBITDA
-$761.24M
Operating Cash Flow
-$170.98M
Capital Expenditure
-$1.58M
Free Cash Flow
-$172.55M
Cash & ST Invst.
$386.26M
Total Debt
$323.78M
Mirum Pharmaceuticals Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$159.88M
+43.3%
Gross Profit
$131.00M
+47.9%
Gross Margin
81.94%
N/A
Market Cap
$7.01B
N/A
Market Cap/Employee
$20.99M
N/A
Employees
334
N/A
Net Income
-$790.16M
-5283.6%
EBITDA
-$779.19M
-19379.8%
Quarterly Fundamentals
Total Cash
$386.26M
+39.1%
Total Debt
$323.78M
+2.1%
Accounts Receivable
$133.11M
+38.9%
Inventory
$25.52M
+13.8%
Long Term Debt
$321.43M
+1.9%
Short Term Debt
$2.35M
+43.1%
Return on Assets
-89.67%
N/A
Return on Invested Capital
-11.34%
N/A
Free Cash Flow
-$229.43M
-11359.9%
Operating Cash Flow
-$228.76M
-11565.6%